This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

LadRx Valuation

Is CX5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CX5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CX5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CX5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CX5?

Key metric: As CX5 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CX5. This is calculated by dividing CX5's market cap by their current book value.
What is CX5's PB Ratio?
PB Ratio	-0.5x
Book	-US$1.81m
Market Cap	US$988.40k

CX5 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-0.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does CX5's PB Ratio compare to its peers?

The above table shows the PB ratio for CX5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	14x
T5O bioXXmed	8x	n/a	€863.1k
CNW co.don	1x	n/a	€6.5m
MDG1 Medigene	0.8x	11.0%	€16.7m
VSC 4SC	46x	n/a	€50.2m
CX5 LadRx	n/a	n/a	€988.4k

Price-To-Book vs Peers: CX5 has negative equity and a Price-To-Book Ratio (-0.5x) compared to the peer average (0.7x).

Price to Book Ratio vs Industry

How does CX5's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
V9Z Aceragen	0.1x	n/a	US$3.12m
V9Z Aceragen	0.1x	n/a	US$2.18m
O7P NeuBase Therapeutics	0.1x	n/a	US$1.39m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: CX5 has negative equity and a Price-To-Book Ratio (-0.5x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is CX5's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CX5 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CX5's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

-3.9%

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

1.4%

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

-1.0%

-31.3%